Previous Issue|Next Issue
Export Citation(s)Download PDF(s)

Proceedings of the 7th Paris Hepatitis Conference International Conference of the Management of Patients with Viral Hepatitis, 13–14 January 2014, Paris, France. Guest Editors: Patrick Marcellin and Tarik Asselah. The publication of this supplement was supported by an unrestricted educational grant from Gilead, Janssen Therapeutics, Janssen, Bristol-Myers Squibb, Roche, Boehringer Ingelheim, Merck, AbbVie, Novartis, Idenix and Alios.

Editorial

Free Access

Viral hepatitis: Impressive advances but still a long way to eradication of the disease

Patrick Marcellin,  Tarik Asselah, 
  • Pages: 1-3
  • First Published: 23 December 2013

Review Articles

Free Access

How to optimize current therapy of HCV genotype 1 infection with boceprevir

Marc Bourlière,  Xavier Adhoute,  Astrid Wendt,  Christelle Ansaldi,  Valérie Oules,  Paul Castellani, 
  • Pages: 4-10
  • First Published: 23 December 2013
Free Access

Is there still a role for PEG IFN+RBV therapy in patients with HCV genotype 1?

Lawrence Serfaty, 
  • Pages: 11-12
  • First Published: 23 December 2013
Free Access

How to optimize current treatment of genotype 2 hepatitis C virus infection

Sebastián Marciano,  Adrián C. Gadano, 
  • Pages: 13-17
  • First Published: 23 December 2013
Free Access

Treatment of hepatitis C virus genotype 3-infection

Stanislas Pol,  Anaïs Vallet-Pichard,  Marion Corouge, 
  • Pages: 18-23
  • First Published: 23 December 2013
Free Access

Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues

Gamal Esmat,  Mohamed El Kassas,  Mohamed Hassany,  Mohamed Gamil,  Maissa El Raziky, 
  • Pages: 24-28
  • First Published: 23 December 2013
Free Access

A brief history of hepatitis milestones

Christian Trepo, 
  • Pages: 29-37
  • First Published: 23 December 2013
Free Access

Management of HCV patients with cirrhosis with direct acting antivirals

Vincenzo Boccaccio,  Savino Bruno, 
  • Pages: 38-45
  • First Published: 23 December 2013
Free Access

Management of HCV transplant patients with triple therapy

Audrey Coilly,  Bruno Roche,  Jean-Charles Duclos-Vallée,  Didier Samuel, 
  • Pages: 46-52
  • First Published: 23 December 2013
Free Access

Treating HCV in HIV 2013: on the cusp of change

Valérie Martel-Laferrière,  Douglas T. Dieterich, 
  • Pages: 53-59
  • First Published: 23 December 2013
Free Access

Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir

Tarik Asselah,  Patrick Marcellin, 
  • Pages: 60-68
  • First Published: 23 December 2013
Free Access

HCV direct-acting antiviral agents: the best interferon-free combinations

Raymond Schinazi,  Philippe Halfon,  Patrick Marcellin,  Tarik Asselah, 
  • Pages: 69-78
  • First Published: 23 December 2013
Free Access

HCV F1/F2 patients: treat now or continue to wait

Mitchell L. Shiffman,  Yves Benhamou, 
  • Pages: 79-84
  • First Published: 23 December 2013
Free Access

Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?

Vincenza Calvaruso,  Antonio Craxì, 
  • Pages: 85-90
  • First Published: 23 December 2013
Free Access

Hepatitis B: are non-invasive markers of liver fibrosis reliable?

Laurent Castera, 
  • Pages: 91-96
  • First Published: 23 December 2013
Free Access

HBsAg quantification: useful for monitoring natural history and treatment outcome

Michelle Martinot-Peignoux,  Martine Lapalus,  Tarik Asselah,  Patrick Marcellin, 
  • Pages: 97-107
  • First Published: 23 December 2013
Free Access

HBeAg-positive chronic hepatitis B: Why do I treat my patients with Nucleos(t)ide Analogs?

Maria Buti, 
  • Pages: 108-111
  • First Published: 23 December 2013
Free Access

HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?

Jia-Horng Kao, 
  • Pages: 112-119
  • First Published: 23 December 2013
Free Access

HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?

Mauro Viganò,  Giampaolo Mangia,  Pietro Lampertico, 
  • Pages: 120-126
  • First Published: 23 December 2013
Free Access

HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?

Jiannis Vlachogiannakos,  George V. Papatheodoridis, 
  • Pages: 127-132
  • First Published: 23 December 2013
Free Access

Alternative interferons and immunomodulators in the treatment of hepatitis C

Hawwa Alao,  T. Jake Liang, 
  • Pages: 133-138
  • First Published: 23 December 2013
Free Access

Impact of HBV therapy on the incidence of hepatocellular carcinoma

Michela Triolo,  Cristina Della Corte,  Massimo Colombo, 
  • Pages: 139-145
  • First Published: 23 December 2013
Free Access

New therapeutic perspectives in HBV: when to stop NAs

Cristina Pérez-Cameo,  Mònica Pons,  Rafael Esteban, 
  • Pages: 146-153
  • First Published: 23 December 2013